Reconstruction lutetium octreotate
By Lucien Hordijk, | 9 January, 2019
Steve Jobs’ private plane, parked at Rotterdam Airport. It is September 2008 when local reporters receive tips about the arrival of Apple’s CEO in the Netherlands. What is the billionaire doing here? It took until 2015 before Ahmed Aboutaleb, the mayor of Rotterdam, revealed the secret: Jobs was treated in the Erasmus University Medical Center for a rare neuroendocrine tumor. As it turns out, Jobs wasn’t the only one.
Since 2000, the hospital has treated more than 1,500 patients from the Netherlands and abroad with neuroendocrine tumors using lutetium octreotate therapy. This unique drug turned out to be so successful that the Antoni van Leeuwenhoek Hospital in Amsterdam and the University Medical Centre Utrecht now also offer the treatment.
However, the three hospitals may soon have to refer their patients abroad for this treatment. The pharmaceutical company Novartis bought the drug, registered it with the European Medicines Agency (EMA) as a treatment for a rare disease and increased the price five-fold.
This reconstruction was originally published in the Dutch Journal of Medicine. Read the full article (Dutch) here.
More investigations
Goliath vs. David: The race to the EU defense money
The war in Ukraine has unveiled a new threat to Europe’s security: Russia’s deployment of hypersonic missiles. With their unparalleled speed and maneu
The Investigative Desk Newsletter special edition July 2023
Read the full newsletter here. Dear readers, In this special edition we present you two major stories we just published. An international team,
Big Tobacco’s Beyond Nicotine Strategy
The past few years, the four biggest tobacco companies (Philip Morris International/Altria, British American Tobacco, Japan Tobacco International and
Why Europe is failing to provide Ukraine with sufficient ammunition
Since the February 2022 invasion, Ukraine’s five main military partners alone (US, Germany, UK, Poland, and the Netherlands) pledged more than 60 bill
The Investigative Desk Newsletter Q2 2023
Read the full newsletter here. Dear reader, This time, we bring you two stories and a book. Our editor Tim Luimes investigated the lobbying activitie
Chemicals lobby moves full steam ahead to undermine pfas ban
Europe wants to ban all pfas at once. The chemical industry is lobbying for the exemption of fluoropolymers. These substances, a type of plastics, are
